These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 10026069)

  • 1. Questions about palivizumab (Synagis).
    Lee SL; Robinson JL
    Pediatrics; 1999 Feb; 103(2):535; author reply 535-6. PubMed ID: 10026069
    [No Abstract]   [Full Text] [Related]  

  • 2. Questions about palivizumab (Synagis).
    Eppes SC
    Pediatrics; 1999 Feb; 103(2):534-5; author reply 535-6. PubMed ID: 10026068
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
    Robinson JL
    Curr Med Res Opin; 2009 Jul; 25(7):1631-2; author reply 1632-3. PubMed ID: 19480611
    [No Abstract]   [Full Text] [Related]  

  • 5. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comments on palivizumab (Synagis).
    Moler FW; Brown RW; Faix RG; Gilsdorf JR
    Pediatrics; 1999 Feb; 103(2):495-7. PubMed ID: 9925848
    [No Abstract]   [Full Text] [Related]  

  • 7. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations.
    Rackham OJ; Thorburn K; Kerr SJ
    Cardiol Young; 2005 Jun; 15(3):251-5. PubMed ID: 15865826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
    Pin I; Pilenko C; Bost M
    Allerg Immunol (Paris); 2002 Dec; 34(10):371-4. PubMed ID: 12575622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economics and RSV.
    Carbonell-Estrany X; Lázaro y de Mercado P
    Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():12-3. PubMed ID: 19651392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palivizumab in the prophylaxis of respiratory syncytial virus infection.
    Cardenas S; Auais A; Piedimonte G
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):719-26. PubMed ID: 16207163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Respiratory syncytial virus infections and preventive options].
    Moll HA; de Groot R
    Ned Tijdschr Geneeskd; 2000 Apr; 144(15):724-5. PubMed ID: 10778722
    [No Abstract]   [Full Text] [Related]  

  • 15. Palivizumab (Synagis) for prevention of RSV infection.
    Med Lett Drugs Ther; 1999 Jan; 41(1043):3-4. PubMed ID: 9924488
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F
    J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost and safety of multidose use of palivizumab vials.
    Gooding J; Millage A; Rye AK; Lacroix R
    Clin Pediatr (Phila); 2008 Mar; 47(2):160-3. PubMed ID: 17901213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
    Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
    Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
    Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
    Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.